BioGend Therapeutics Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 5.91 million compared to TWD 1.35 million a year ago. Net loss was TWD 34.47 million compared to TWD 38.26 million a year ago. Basic loss per share from continuing operations was TWD 0.33 compared to TWD 0.38 a year ago. Diluted loss per share from continuing operations was TWD 0.33 compared to TWD 0.38 a year ago.
For the six months, sales was TWD 10.88 million compared to TWD 2.44 million a year ago. Net loss was TWD 79.1 million compared to TWD 85.1 million a year ago. Basic loss per share from continuing operations was TWD 0.77 compared to TWD 0.85 a year ago. Diluted loss per share from continuing operations was TWD 0.77 compared to TWD 0.85 a year ago.